http://finance.yahoo.com/news/landmark-analysis-two-data-platinum-165500292.htmlMaybe this will finally move the stock!-J&J exited the stent market because they couldn't compete with ABT and BSX.-Now this Landmark Study shows that BSX stent is superior to the ABT stent!
So much for your analysis!
Jumping in here, are we at the bottom?Bubbadog.....
Um, Abbott replaced the Xience V stent with the Xience Prime stent, FDA approval was received by Abbott last year. This study compared a new BSX stent to a now-obsolete Abbott stent. Get your facts straight before betting the ranch on BSX.